Blockade of interleukin-17A protects against coxsackievirus B3-induced myocarditis by increasing COX-2/PGE2 production in the heart

FEMS Immunology and Medical Microbiology

Volumn 64, Issue 3, 2012, Pages 343-351

  Xie, Yuquan ^a   Chen, Ruizhen ^a   Zhang, Xian ^a   Yu, Yong ^a   Yang, Yingzhen ^a   Zou, Yunzeng ^a   Ge, Junbo ^a   Chen, Haozhu ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Cyclooxygenase; Interleukin 17; Myocarditis; Prostaglandins

Indexed keywords

CYCLOOXYGENASE 2; INTERLEUKIN 17; INTERLEUKIN 17 ANTIBODY; PROSTAGLANDIN E2; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; COXSACKIE VIRUS B3; CYTOKINE RESPONSE; ENZYME INDUCTION; HEART; HEART MUSCLE INJURY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; SPLEEN; TH17 CELL; VIRUS MYOCARDITIS; VIRUS REPLICATION;

ANIMALS; COXSACKIEVIRUS INFECTIONS; CYCLOOXYGENASE 2; DINOPROSTONE; ENTEROVIRUS B, HUMAN; HELA CELLS; HUMANS; INTERLEUKIN-17; MICE; MICE, INBRED BALB C; MYOCARDITIS; MYOCARDIUM; SPLEEN; TH17 CELLS; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA; VIRUS REPLICATION;

EID: 84858161126     PISSN: 09288244     EISSN: 1574695X     Source Type: Journal    
DOI: 10.1111/j.1574-695X.2011.00918.x     Document Type: Article

References (30)

1. Baboonian C & McKenna W (2003) Eradication of viral myocarditis: is there hope? J Am Coll Cardiol 42: 473-476.
2. Baldeviano GC, Barin JG, Talor MV, Srinivasan S, Bedja D, Zheng D, Gabrielson K, Iwakura Y, Rose NR & Cihakova D (2010) Interleukin-17A is dispensable for myocarditis but essential for the progression to dilated cardiomyopathy. Circ Res 106: 1646-1655.
3. Bing RJ & Lomnicka M (2002) Why do cyclo-oxygenase-2 inhibitors cause cardiovascular events? J Am Coll Cardiol 39: 521-522.
4. Chen P, Xie Y, Shen E et al. (2011) Astragaloside IV attenuates myocardial fibrosis by inhibiting TGF-beta1 signaling in coxsackievirus B3-induced cardiomyopathy. Eur J Pharmacol 658: 168-174.
5. Domingues HS, Mues M, Lassmann H, Wekerle H & Krishnamoorthy G (2010) Functional and pathogenic differences of Th1 and Th17 cells in experimental autoimmune encephalomyelitis. PLoS ONE 5: e15531.
6. Dowd NP, Scully M, Adderley SR, Cunningham AJ & Fitzgerald DJ (2001) Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo. J Clin Invest 108: 585-590.
7. Fairweather D & Rose NR (2007) Coxsackievirus-induced myocarditis in mice: a model of autoimmune disease for studying immunotoxicity. Methods 41: 118-122.
8. Fairweather D, Kaya Z, Shellam GR, Lawson CM & Rose NR (2001) From infection to autoimmunity. J Autoimmun 16: 175-186.
9. Fairweather D, Frisancho-Kiss S, Yusung SA, Barrett MA, Davis SE, Gatewood SJ, Njoku DB & Rose NR (2004) Interferon-gamma protects against chronic viral myocarditis by reducing mast cell degranulation, fibrosis, and the profibrotic cytokines transforming growth factor-beta 1, interleukin-1 beta, and interleukin-4 in the heart. Am J Pathol 165: 1883-1894.
10. Fairweather D, Frisancho-Kiss S, Yusung SA, Barrett MA, Davis SE, Steele RA, Gatewood SJ & Rose NR (2005) IL-12 protects against coxsackievirus B3-induced myocarditis by increasing IFN-gamma and macrophage and neutrophil populations in the heart. J Immunol 174: 261-269.
11. Feldman AM & McNamara D (2000) Myocarditis. N Engl J Med 343: 1388-1398.
12. Grinde B, Gayorfar M & Hoddevik G (2007) Modulation of gene expression in a human cell line caused by poliovirus, vaccinia virus and interferon. Virol J 4: 24.
13. Howard PA & Delafontaine P (2004) Nonsteroidal anti-inflammatory drugs and cardiovascular risk. J Am Coll Cardiol 43: 519-525.
14. Juarranz Y, Abad C, Martinez C, Arranz A, Gutierrez-Canas I, Rosignoli F, Gomariz RP & Leceta J (2005) Protective effect of vasoactive intestinal peptide on bone destruction in the collagen-induced arthritis model of rheumatoid arthritis. Arthritis Res Ther 7: R1034-R1045.
15. Juni P, Dieppe P & Egger M (2002) Risk of myocardial infarction associated with selective COX-2 inhibitors: questions remain. Arch Intern Med 162: 2639-2640.
16. Kanda N, Koike S & Watanabe S (2005) IL-17 suppresses TNF-alpha-induced CCL27 production through induction of COX-2 in human keratinocytes. J Allergy Clin Immunol 116: 1144-1150.
17. Kiefer W & Dannhardt G (2002) COX-2 inhibition and the control of pain. Curr Opin Investig Drugs 3: 1348-1358.
18. Knowlton KU (2008) CVB infection and mechanisms of viral cardiomyopathy. Curr Top Microbiol Immunol 323: 315-335.
19. Li H, Bradbury JA, Dackor RT et al. (2011) Cyclooxygenase-2 (COX-2) regulates Th17 cell differentiation during allergic lung inflammation. Am J Respir Crit Care Med 184: 37-49.
20. Mengle-Gaw LJ & Schwartz BD (2002) Cyclooxygenase-2 inhibitors: promise or peril? Mediators Inflamm 11: 275-286.
21. Miric M, Miskovic A, Brkic S, Vasiljevic J, Keserovic N & Pesic M (1994) Long-term follow-up of patients with myocarditis and idiopathic dilated cardiomyopathy after immunomodulatory therapy. FEMS Immunol Med Microbiol 10: 65-74.
22. Nishikubo K, Imanaka-Yoshida K, Tamaki S, Hiroe M, Yoshida T, Adachi Y & Yasutomi Y (2007) Th1-type immune responses by Toll-like receptor 4 signaling are required for the development of myocarditis in mice with BCG-induced myocarditis. J Autoimmun 29: 146-153.
23. Noutsias M, Rohde M, Goldner K et al. (2011) Expression of functional T-cell markers and T-cell receptor Vbeta repertoire in endomyocardial biopsies from patients presenting with acute myocarditis and dilated cardiomyopathy. Eur J Heart Fail 13: 611-618.
24. Poffenberger MC, Straka N, El WN, Fang D, Shanina I & Horwitz MS (2009) Lack of IL-6 during coxsackievirus infection heightens the early immune response resulting in increased severity of chronic autoimmune myocarditis. PLoS ONE 4: e6207.
25. Rother M, Krohn S, Kania G et al. (2010) Matricellular signaling molecule CCN1 attenuates experimental autoimmune myocarditis by acting as a novel immune cell migration modulator. Circulation 122: 2688-2698.
26. Samad TA, Moore KA, Sapirstein A, Billet S, Allchorne A, Poole S, Bonventre JV & Woolf CJ (2001) Interleukin-1beta-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature 410: 471-475.
27. Schjerning OA, Fosbol EL, Lindhardsen J et al. (2011) Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation 123: 2226-2235.
28. Stamp LK, Cleland LG & James MJ (2004) Upregulation of synoviocyte COX-2 through interactions with T lymphocytes: role of interleukin 17 and tumor necrosis factor-alpha. J Rheumatol 31: 1246-1254.
29. Takahashi T, Zhu SJ, Sumino H, Saegusa S, Nakahashi T, Iwai K, Morimoto S & Kanda T (2005) Inhibition of cyclooxygenase-2 enhances myocardial damage in a mouse model of viral myocarditis. Life Sci 78: 195-204.
30. Xie Y, Chen R, Zhang X et al. (2011) The role of Th17 cells and regulatory T cells in Coxsackievirus B3-induced myocarditis. Virology 421: 72-84.